Genmab — November 2014
-
Hvis nogen (j&j er måske dem der er tættest på resultaterne) ser potentialet napper de Gen i et snuptag. Kurs 500 og Jan fortsætte i selskabet, nu som meget velhavende. ATP og GSK tjener på det og de fleste småaktionærene kan ikke sige nej til kurs 500.
-
Thanks, Thomas. Why don't I take questions one and three, and then part number two on Arzerra for David? Why don't we start with HexaBody? We're in very active discussions with multiple parties on giving them access to our HexaBody technology platform. We also have a number of internal programs which uses HexaBody with excellent proof-of -concept. We already presented some of that proof-of- concept data at ASH last year in an oral presentation.
-
But I can assure you that you will see more partnerships being executed by Genmab. Also some that you have qualified as more substantial, albeit that the first HexaBody agreement that we have entered into is with a very large blue-chip biotech company for multiple programs, I can assure you. We also believe that one is very substantial, but we are waiting on their experience with the platform. But we are, in fact, having a lot of activity in that area and there will be- there is anticipated more
-
Hver gang Genmab præsenterer deres forventninger til året, så bliver de ved at nævne at det er uden nye aftaler (selvfølgelig), men et eller andet sted har det hele tiden lydt som om de forventer en eller flere i år der vil påvirke årets resultat, så kom nu med den brede Gilead aftale
-
Hvis ikke han har leveret inden post ash seminaret bør vi trykke lidt til ham der
-
Peter Aabo hæver sin anbefaling på genmab ret markant
-
fra 135 til 181 i kursmål
-
Han siger 40% chance for at dara kan godkendes i 2017 og at arzerra aldrig vil være andet end et niche produkt
-
Indregner 88 kr, pr. aktie for daratumumab. resten er stort set cash og skatteaktiv. Arzerra og teknogierne mv. for ingen værdi stort set
-
Men okay, en af Peter Aabo mener også at Imbruvica er stærkt i front line CLL pt. Ved dog ikke om manden ikke følger med i hvad der reelt sker for Imbruvica er slet ikke godkendt i frontline behandling
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind